Search the Newsreel

Adage Capital group (SCYX) discloses 1,041,824-share SCYNEXIS stake including warrants

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has reported a beneficial ownership of 1,041,824 shares of SCYNEXIS, Inc. common stock, which includes 498,346 shares issuable upon the exercise of warrants. This stake represents 9.99% of SCYNEXIS's outstanding common stock, calculated …

SCYNEXIS Inc (SCYX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for SCYNEXIS Inc (SCYX), highlighting its current earnings forecast score, analyst ratings, and price targets. Based on 3 analysts, the stock has an average price target of $4.00 and a "Buy" trend. The report also details past and …

SCYNEXIS Swings To Q2 Profit; Expects Phase 1 Topline Data For SCY-770 In Q3 2026;Stock Up

(RTTNews) - SCYNEXIS, Inc. (SCYX), a clinical-stage biotechnology company, reported financial results for the second quarter ended June 30, 2026, swinging to a net profit compared to a loss last year. In addition, the company provided an update on its investigational pipeline. Company Profile …

Scynexis Inc earnings beat by $1.14, revenue topped estimates

Scynexis Inc (NASDAQ: SCYX) reported strong second-quarter results, beating analyst EPS estimates by $1.14 with an EPS of $0.630. The company also exceeded revenue expectations, bringing in $240K against a consensus estimate of $80.33K. Despite the positive earnings, Scynexis Inc's stock has seen a …

Scynexis Q2 adjusted EPS misses estimate as sales decline 82.77%

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update

SCYNEXIS, Inc. (NASDAQ: SCYX) announced its second quarter 2026 financial results, highlighting a strong cash position of $71.1 million, which is expected to fund operations into 2029. The company provided updates

SCYNEXIS (NASDAQ:SCYX) Announces Quarterly Earnings Results, Beats Expectations By $1.14 EPS

SCYNEXIS GAAP EPS of $0.63 beats by $1.14, revenue of $0.24M beats by $0.16M

* SCYNEXIS press release [https://seekingalpha.com/pr/20613730-scynexis-reports-second-quarter-2026-financial-results-and-provides-corporate-update] (SCYX [https://seekingalpha.com/symbol/SCYX]): Q2 GAAP EPS of $0.63 beats by $1.14. * Revenue of $0.24M (-82.4% Y/Y) beats by $0.16M. * Cash, cash equivalents and investments totaled $71.1 million on June 30, 2026, compared to $56.3 million on December 31, …

Scynexis (NASDAQ: SCYX) lifts cash and pipeline with Q2 2026 moves

SCYNEXIS (SCYX) Earnings Date and Reports 2026

SCYNEXIS (NASDAQ:SCYX) Lowered to Strong Sell Rating by Wall Street Zen

Wall Street Zen downgraded SCYNEXIS (NASDAQ:SCYX) from a "sell" to a "strong sell" rating. Despite this, the stock holds an overall "Hold" consensus rating with an average price target of $24.00. The biopharmaceutical company, which develops antifungal therapies, saw its shares rise by 0.8% …

SCYNEXis Inc (SCYX) Stock News Today

This article provides current stock news for SCYNEXIS Inc (SCYX) from TradingKey. It displays the latest stock price, market cap, and links to various financial data and analysis sections for the company. The article notes that more news is coming soon for SCYX.

Scynexis Ongoing Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against SCYNEXIS, Inc. (NASDAQ: SCYX) and reminds investors of the January 8, 2024, deadline to seek the role of lead plaintiff in a federal securities class action. The investigation stems from allegations that Scynexis made false …

SCYNEXIS (SCYX) Projected to Post Quarterly Earnings on Wednesday

12 Health Care Stocks Moving In Friday's Intraday Session

This article identifies 12 healthcare stocks that experienced significant movement during Friday's intraday trading session. It highlights both gainers, such as Replimune Group and SCYNEXIS, which saw substantial increases, and losers like Karyopharm Therapeutics and Nuwellis, which experienced notable declines. The report provides specific …

SCYNEXIS Inc (SCYX) Financial Health: Profitability & Balance Sheet Analysis

The article provides a financial health analysis of SCYNEXIS Inc (SCYX), reporting its current financial score as 9.29, ranking 3 out of 155 in the Pharmaceuticals industry. The company's financial status is described as robust with high operating efficiency, despite a significant year-over-year decrease …

SCYNEXIS Inc (SCYX) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for SCYNEXIS Inc (SCYX), noting its current valuation score of 9.32, ranking 21st in the Pharmaceuticals industry. It highlights the company's current P/E ratio of -10.06, which is significantly below its recent high. The article also indicates that …

SCYNEXIS Inc (SCYX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for SCYNEXIS Inc (SCYX), ranking it 104 out of 155 in the Pharmaceuticals industry with a score of 3.19. Key metrics such as beta, VaR, maximum drawdown, volatility, and Sharpe Ratio are presented to detail the stock's performance …

SCYX|SCYNEXIS Inc|Price:3.770|Chg%:+0.140

SCYNEXIS Inc. (SCYX) shows strong fundamentals, high growth potential, and is considered fairly valued within the Pharmaceuticals industry. Analysts have rated it as a "Buy" with a significant upside potential of 839.68%. The company is pioneering medicine for difficult-to-treat infections, with its antifungal platform …

SCYNEXIS Inc (SCYX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article discusses the revenue breakdown of SCYNEXIS Inc (SCYX) by business segments and regions. However, it states that relevant data for these categories have not yet been disclosed by the company. The page provides current stock information for SCYNEXIS Inc, including its market …

SCYNEXIS Inc (SCYX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of SCYNEXIS Inc (SCYX), detailing its current price momentum, support and resistance levels, and various technical indicator readings. It also includes an analysis of moving averages and offers a summary of signals based on these technical tools. The …

SCYNEXIS Inc (SCYX) Income Statement

This article provides the quarterly and annual income statements for SCYNEXIS Inc (SCYX), detailing financial performance metrics such as total revenue, operating expenses, net income, and earnings per share over several fiscal years and quarters. It also includes an FAQ section explaining how to …

SCYNEXIS Inc (SCYX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical data on dividends and stock splits for SCYNEXIS Inc (SCYX). It indicates that SCYNEXIS has not distributed any dividends over the past five years. The company has undergone several stock splits, including a 1-for-8 merger in May 2026 and multiple …

SCYNEXIS, Inc. Revenue Breakdown – LSE:0L49

SCYNEXIS, Inc. (LSE:0L49) reported its financial performance for the last year, generating $20.60 million USD. The vast majority of this revenue, $20.60 million USD, came from its Drug Development segment, showing a significant increase from $3.75 million USD in the previous year. The United …

SCYNEXIS Inc (SCYX) Institutional Confidence

SCYNEXIS Inc's institutional shareholding score is 3.00, placing it 92nd out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion decreased by 22.57% quarter-over-quarter to 25.24%. James Simons is the largest institutional shareholder, holding 0.28% of shares outstanding.

Federated Hermes (SCYX) group discloses 4.03% Scynexis stake in amended 13G

Federated Hermes, Inc. and related parties, including the Voting Shares Irrevocable Trust and the Donahue family, have disclosed a 4.03% beneficial ownership stake in SCYNEXIS, Inc. (SCYX) common stock. This amended 13G filing reports ownership of 441,658 shares as of June 30, 2026. The …

SCYNEXIS Inc. (SCYX) Q1 2026 Earnings: Wider-than-Expected Loss on No Reported Revenue; Stock Rises 5.17%

SCYX Forecast — Price Target — Prediction for 2027

SCYX Q1 2026 Earnings: EPS Misses Estimates by Wide Margin as Cash Burn Continues Without Revenue - Guidance Upgrade Report

SCYNEXIS INC (NASDAQ:SCYX) Combines Minervini Trend Template with High-Growth Momentum Fundamentals

SCYNEXIS lands cash to fund rare disease drug work into mid-2029

Scynexis Inc (SCYX) News, Articles, Events & Latest Updates

Scynexis Stock Price Forecast. Should You Buy SCYX?